Organovo Holdings, Inc. (ONVO) is a commercial-stage company focused on developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D that mimic native human tissue composition, architecture, and function. Its platform, NovoGen Bioprinters, is focused on multiple 3D bioprinting technologies. Its commercial tissue exVive3D Human Liver Tissue is designed to be used for predictive preclinical testing of drug compounds. It is developing 3D Human Kidney Tissue, which can be used for predictive preclinical testing of drug compounds.
Reported after close today (6/9/16) Earnings: EPS -$0.10 Revenue $306K Estimates: EPS -$0.09 Revenue $466.7K Up 7.59% after hours
Organovo Prices Approximately $25 Million Public Offering of Common Stock http://finance.yahoo.com/news/organovo-prices-approximately-25-million-131155923.html